Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Spyre Therapeutics | Aeglea BioTherapeutics

Biotech & Life Sciences · Waltham, United States · Founded 2013 · IPO 2016 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$5.98B
Market cap · 2026
Revenue
$886K
Latest reported FY

Investors

20 investors on Spyre Therapeutics | Aeglea BioTherapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 4 investors entered at this stage
Novartis Venture Fund
UT Horizon Fund
KBI Biopharma
Lilly Ventures
Series B+ 16 investors entered at this stage
Affinity Asset Advisors
Venrock
Access Industries
Fairmount Funds Management
Boxer Capital
New Ground Ventures
RTW Investments
Woodline Partners
Perceptive Advisors
Deep Track Capital
Great Point Capital
Commodore Capital
Braidwell
Venrock Healthcare Capital Partners
Polar Capital
Cormorant Asset Management

Global footprint

Where Spyre Therapeutics | Aeglea BioTherapeutics has talent and traffic

Web traffic by country
11K monthly visits
across markets
🇺🇸 United States62.7%
🇮🇳 India23.6%
🇯🇵 Japan15.5%
Top 3 markets shown

See Spyre Therapeutics | Aeglea BioTherapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo